[新聞] AZ抗體療法失敗

看板Gossiping作者st900278 (喵咪喵喵叫)時間2年前 (2021/06/15 18:54)推噓2(4推 2噓 6→)

留言12則, 8人參與討論串1/1

備註請放最後面違者新聞文章刪除 1.媒體來源: ※ 例如蘋果日報、自由時報（請參考版規下方的核准媒體名單）路透社 REUTERS 2.記者署名: ※ 若新聞沒有記者名字或編輯名字，請勿張貼，否則會被水桶14天 ※ 外電至少要有來源或編輯如:法新社 Vishwadha Chander 3.完整新聞標題: ※ 標題沒有完整寫出來 ---> 依照板規刪除文章 AstraZeneca says antibody treatment failed in preventing COVID-19 in exposed patients 4.完整新聞內文: ※ 社論特稿都不能貼！違者刪除（政治類水桶3個月)，貼廣告也會被刪除喔！可詳看版規 (Reuters) -Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus. The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days. AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported. “While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” Mene Pangalos, AstraZeneca executive vice president, said in a statement. AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease. The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection. Rivals Regeneron Pharmaceuticals Inc and Eli Lilly & Co have both developed monoclonal antibody therapies which have been authorised for use in the United States to treat patients infected with the virus.. The European Medicines Agency (EMA) has approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion and one developed by GlaxoSmithKline and Vir Biotechnology Inc. AstraZeneca in October enlisted Swiss contract manufacturer Lonza to produce the antibody drug in Portsmouth, New Hampshire, starting in the first half of 2021. AZD7442 is being developed with support from the U.S. government. AstraZeneca in March announced a deal with the U.S. government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the U.S. government regarding next steps on the deal. AZ的抗體療法AZD7442實驗結果不好 AZD7442比安慰劑減少了33%的發病的機率但沒有達到顯著 5.完整新聞連結 (或短網址): ※ 當新聞連結過長時，需提供短網址方便網友點擊 https://reut.rs/3zuRCi7 6.備註: ※ 一個人三天只能張貼一則新聞，被刪或自刪也算額度內，超貼者水桶，請注意 ※ 備註請勿張貼三日內新聞(包含連結、標題等) -- ※ 發信站: 批踢踢實業坊(ptt.cc), 來自: 157.147.34.142 (日本) ※ 文章網址: https://www.ptt.cc/bbs/Gossiping/M.1623754473.A.D5C.html

噓

signm

06/15 18:55, 2年前 , 1^F

06/15 18:55, 1^F

→

soarling

06/15 18:56, 2年前 , 2^F

06/15 18:56, 2^F

推

JohnnyJack11

06/15 18:58, 2年前 , 3^F

06/15 18:58, 3^F